2020 Atypical Drug Discovery Review, released by the aHUS Alliance
2020 overview of atypical HUS therapeutic drug development, by the aHUS Alliance
OMS721: Omeros Research Collaboration with University of Cambridge
Pharma News: an Atypical HUS update from the aHUS Alliance. In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, but how will it engage other aHUS stakeholders interested in OMS721 clinical trials and atypical HUS advancements in research?
Genetic tests – to know or not?
Genetics is very important to aHUS patients. aHUS is a very rare genetic diseases. aHUS patients get to know and understand…